EIKN
EIKN clinical trials: Eikon Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Eikon Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 10
- As lead sponsor
- 1
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
EIKN on the catalyst calendar · EIKN registry changes
- Primary completion Dec 31, 2035Sponsor estimatePhase 2/Phase 3NCT07365319A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell...Eikon Therapeutics · Non Small Cell Lung Cancer (Squamous or Non Squamous)RecruitingEIKNLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimatePhase 1/Phase 2NCT07262619EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With...Eikon Therapeutics · Advanced Solid TumorsRecruitingEIKNLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2035Sponsor estimatePhase 2/Phase 3NCT06697301Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.Eikon Therapeutics · Advanced MelanomaRecruitingEIKNLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2027Sponsor estimatePhase 1/Phase 2NCT06253130A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid TumorsEikon Therapeutics · Advanced Solid TumorRecruitingEIKNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06246110A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCEikon Therapeutics · NSCLCActive, not recruitingEIKNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2024ActualPhase 1NCT04840394Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsEikon Therapeutics · Tumor, SolidCompletedEIKNLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2023ActualPhase 2NCT04819373BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid TumorsEikon Therapeutics · Tumor, SolidCompletedEIKNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2024ActualPhase 1NCT04196530BDB001-102: Open Label Dose Escalation of BDB001 in Combination w AtezolizumabEikon Therapeutics · Tumor, SolidCompletedEIKNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2024ActualPhase 1NCT03486301BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With PembrolizumabEikon Therapeutics · Tumor, SolidCompletedEIKNLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 1/Phase 2NCT06907043A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.Eikon Therapeutics · Advanced Solid TumorsRecruitingEIKNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT03915678Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid TumorsInstitut Bergonié · Solid Tumor, AdultActive, not recruitingEIKNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner